NCT06864624View on ClinicalTrials.gov

Perioperative Treatment of Sunvozertinib in Stage II-IIIB NSCLC

PHASE2RecruitingINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

February 18, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

June 30, 2029

Conditions
NSCLC
Interventions
DRUG

Sunvozertinib

Neoadjuvant stage: 300mg for 12 weeks Adjuvant stage: 300mg for first 4 weeks, then 150mg for up to 2 years

Trial Locations (3)

Unknown

NOT_YET_RECRUITING

Second Xiangya Hospital of Central South University, Changsha

NOT_YET_RECRUITING

General Hospital of Ningxia Medical University, Yinchuan

RECRUITING

Tangdu Hospital, Xi'an

Sponsors
All Listed Sponsors
collaborator

Dizal (Jiangsu) Pharmaceutical Co., Ltd.

INDUSTRY

lead

Tang-Du Hospital

OTHER

NCT06864624 - Perioperative Treatment of Sunvozertinib in Stage II-IIIB NSCLC | Biotech Hunter | Biotech Hunter